Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically diagnosed glioblastoma multiforme or other malignant glioma~  * Recurrent disease~* Must have received prior temozolomide~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* SGOT ≤ 2.5 times upper limit of normal (ULN)~* Creatinine ≤ 2 times ULN~* Bilirubin ≤ 2 times ULN~* No other active malignancy except for cervical carcinoma in situ or basal cell carcinoma of the skin~* No serious medical or psychiatric illness that, in the opinion of the investigator, would preclude study treatment~* No medical condition that precludes swallowing pills~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).